Photon imager optima

Manufactured by Biospace

Sourced in France

The Photon Imager Optima is a high-performance imaging system designed for scientific research applications. It captures and analyzes low-level luminescent signals with high sensitivity and resolution. The core function of the Photon Imager Optima is to provide accurate and quantitative measurements of luminescent samples.

Automatically generated - may contain errors

Lab products found in correlation

M3 vision software, by Biospace (6 mentions) Luciferin, by GoldBio (2 mentions) Crl nu foxn1nu mice, by Charles River Laboratories (1 mentions) D luciferin, by Thermo Fisher Scientific (1 mentions) M3vision analysis software, by Biospace (1 mentions) Nev10011ex, by PerkinElmer (1 mentions) Vivaspin 500 centrifugal, by Sartorius (1 mentions) Luminol derivative l 012, by Fujifilm (1 mentions) D luciferin, by Biosynth (1 mentions) D luciferin, by Promega (1 mentions) Vivoglo, by Promega (1 mentions) Doxycycline, by Merck Group (1 mentions) Interleukin 2 (il 2), by Thermo Fisher Scientific (1 mentions) Luciferin, by Merck Group (1 mentions) M3 vision, by Biospace (1 mentions) D luciferin, by Interchim (1 mentions)

Spelling variants of this product

Photon Imager (81 citations) Optima imager (2 citations)

22 protocols using photon imager optima

In Vivo Tumor Imaging and CAR-T Persistence

Check if the same lab product or an alternative is used in the 5 most similar protocols

For Angiosense imaging, mice-bearing F9 tumors were injected with a single intravenous dose of angiosense 750 (2 nmol/100 µL) as recommended by the manufacturer (NEV10011EX, PerkinElmer). After 24 hours of Angiosense 750 administration, fluorescence accumulation into the tumor was visualized using the PhotonImager Optima (Biospace, Paris, France). Relative fluorescent units were calculated by measuring tumor fluorescence divided by tumor volume. For luciferase imaging, and to evaluate CAR-T cell persistence and expansion in vivo, C57BL/6 J mice were injected intravenously with 1×107 EDA CAR-T luciferase or PSMA CAR-T luciferase. Luciferase activity was measured 10 min after intraperitoneal injection of 3 mg/mouse of the substrate D-luciferin (Thermo Fisher Scientific), on days 1, 3, 7, 10 and 14 postinfusion with the PhotonImager Optima and the M3Vision Analysis software (Biospace Lab, France).

Martín-Otal C., Lasarte-Cia A., Serrano D., Casares N., Conde E., Navarro F., Sánchez-Moreno I., Gorraiz M., Sarrión P., Calvo A., De Andrea C.E., Echeveste J., Vilas A., Rodriguez-Madoz J.R., San Miguel J., Prosper F., Hervas-Stubbs S., Lasarte J.J, & Lozano T. (2022). Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells. Journal for Immunotherapy of Cancer, 10(8), e004479.

+ Open protocol

+ Expand

Biodistribution of Lipid Nanocarriers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Biodistribution of LNC was assessed by fluorescence imaging of DiI-LNC (Morille et al., 2010 (link)) using untreated mice as control. Test mice were injected intraperitoneally (i.p.) with 100 μL DiI solution or DiI-LNC dispersion having a similar DiI concentration. Mice were sacrificed 6 h post treatment with a large dose of thiopental (50 mg/kg. i.p.) and their main organs; liver, spleen, kidneys, and heart collected for imaging. Fluorescent signals were visualized at emission wavelength 549 nm and excitation wavelength 565 nm (PhotonIMAGER^TM Optima, Biospace Lab, Nesles-la-Vallée, France).

El-Sheridy N.A., El-Moslemany R.M., Ramadan A.A., Helmy M.W, & El-Khordagui L.K. (2021). Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules. Drug Delivery, 28(1), 906-919.

+ Open protocol

+ Expand

Monitoring Peritoneal Tumor Growth and Targeting in Nude Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Luciferase-expressing SKOV3.IP1 cells (0.5 × 10⁶), kindly provided by Prof. Marc Bracke (UGent, Belgium), were intraperitoneally injected in Crl: NU-Foxn1^Nu mice (Charles River; n = 3) [30 (link),36 (link)]. Tumor growth was followed-up using bioluminescence imaging for 30 days. [¹¹¹In]In-MSAP.2Rs15d (10.5 ± 0.5 MBq, 7.5 µg corresponding to 1 nmol MSAP, and apparent molar specific activity of 11.6 ± 0.5 GBq/µmol, intravenously) and luciferin (150 mg/kg, intraperitoneally) were administered 1 h and 10 min, respectively prior to SPECT/CT imaging. Then, the animals were killed via cervical dislocation and peritoneal tumor lesions were resected under fluorescence guidance. Finally, fluorescence and radioactive signals of all confirmed tumor lesions, and of the major peritoneal organs were measured ex vivo as described in 2.4.1 and 2.5. Bioluminescence imaging (BLI) (PhotonIMAGER^TM Optima, Biospace, Nesles la Vallée, France) was used to confirm the tumorous character of resected lesions.

Debie P., Declerck N.B., van Willigen D., Huygen C.M., De Sloovere B., Mateusiak L., Bridoux J., Puttemans J., Devoogdt N., van Leeuwen F.W, & Hernot S. (2021). The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery. Biomolecules, 11(3), 360.

+ Open protocol

+ Expand

Biodistribution of Labeled Exosomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Athymic nude mice (n=4 per group) were employed to study biodistribution of exosomes administered via oral and intravenous routes. Animals were fed with purified AIN-93M diet and water ad libitum. Milk exosomes were labeled with near-infrared fluorescent dye DiR (20 μM) by incubation at 37 °C for 30 min, followed by centrifugation at 10,000×g for 30 min to remove unbound dye. Labeled exosomes were concentrated with vivaspin 500 centrifugal filter devices (10,000K MWCO, Sartorius Stedim, Bohemia, New York) and washed thrice with PBS. Exosome pellets were suspended in PBS and sterilized by passing through 0.22 μm filter. Animals were administered with a single dose of 100 μl DiR-labeled exosomes (60 mg/kg Exo protein). Animals were euthanized after 4 days of treatment; different organs were collected and imaged ex vivo using Photon Imager Optima (Biospace lab, Paris, France). The relative intensities were measured and compared with untreated control. For in vivo stability study, after administration of DiR-labeled exosomes by oral gavage as described above, blood were collected at different time points (1, 4, 24, 48, 72 and 144 h) and imaged for fluorescent intensity.

Munagala R., Aqil F., Jeyabalan J, & Gupta R.C. (2015). Bovine milk-derived exosomes for drug delivery. Cancer letters, 371(1), 48-61.

+ Open protocol

+ Expand

In Vivo Liver Transfection and Luciferase Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo liver transfection, 20 μg of reporter plasmids diluted in 1.8 mL of saline was injected as a bolus through the lateral tail vein.²¹ (link) Luciferase activity was determined 48 h later by BLI. To this end, mice were briefly anesthetized with an injection of a ketamine/xylazine mixture (80:10 mg/kg, intraperitoneally [i.p.]). The substrate D-luciferin (REGIS Technologies, Morton Grove, IL) was administered i.p. (100 μL of a 30 μg/μL solution in PBS). Light emission was detected 5, 20, and 30 min later using a PhotonImager Optima apparatus (BioSpace Lab, Nesles-la-Vallée, France). Data were analyzed using the M3Vision software (BioSpace Lab), representing the maximal value obtained for each animal.

Lumbreras S., Ricobaraza A., Baila-Rueda L., Gonzalez-Aparicio M., Mora-Jimenez L., Uriarte I., Bunuales M., Avila M.A., Monte M.J., Marin J.J., Cenarro A., Gonzalez-Aseguinolaza G, & Hernandez-Alcoceba R. (2021). Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis. Molecular Therapy. Methods & Clinical Development, 22, 210-221.

+ Open protocol

+ Expand

In Vivo ROS Monitoring in Wound Healing

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the wound monitoring group (group 2), ROS monitoring was performed on both experimental and control mice on Postoperative Day 2 and 4. The bioluminescence of the ROS in each wound was imaged and quantified using a photon counting imaging system (PhotonIMAGER OPTIMA; Biospace Lab). The Luminol derivative L‐012 (FUJIFILM Wako Pure Chemical Corporation) was administered intraperitoneally (0.5 mg 20 g⁻¹) 50 minutes prior to imaging. Imaging duration was 2 minutes. Regions of Interest (ROI) were placed over the wounds, and counts of Relative Light Units were analyzed using M3 Vision Software (Biospace Lab).

Rosenberg A., Inagaki F., Kato T., Okada R., Wakiyama H., Furusawa A., Choyke P.L, & Kobayashi H. (2020). Wound healing after excision of subcutaneous tumors treated with near‐infrared photoimmunotherapy. Cancer Medicine, 9(16), 5932-5939.

+ Open protocol

+ Expand

Biodistribution of Milk Exosomes in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

To examine the biodistribution of milk-derived exosomes in whole animals, evidence of uptake and tissue distribution was obtained by labeling milk exosomes with a near-IR fluorescent label, DiR (Life Technologies, Carlsbad, Calif.), and treating female nude mice with a single dose of the exosomes administered by oral gavage, intravenously, intranasally, or intraperitoneally (2 mg Exo protein/mouse). Imaging (Biospace lab Photon Imager Optima) of the live animals showed a strong fluorescent signal, with the signal being detected even after 4 d. Harvesting of various organs following euthanasia and imaging showed that the oral gavage (FIG. 28), intravenous (FIG. 29), intranasal (FIG. 30), and intraperitoneal (FIG. 31) routes resulted in similar tissue distribution of the exosomes, with the exceptions that, with intravenous and intraperitoneal administration, the liver was the predominant site of distribution, and that, when intranasal administration was used, the lung was the predominant site. These data indicate that various routes of administration could be utilized effectively for the delivery of the exosomes and for the selection of target organs.

US09943482B2. Milk-derived microvesicle compositions and related methods (2018-04-17). UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. [US]. Inventors: Ramesh C. Gupta [US], Radha Munagala [US], Farrukh Aqil [US], Jeyaprakash Jeyabalan [US].

+ Open protocol

+ Expand

Tumorigenicity and Metastasis Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal studies were approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee (P949) and performed in accordance with the guidelines. For tumorigenicity studies 2.0 × 10⁶ cells in 50 µl of RPMI-1640/10% FCS were injected intra-dermally into each of two sites of six five-week old male BALB/c nude mice. Tumors were measured twice weekly and volume calculated in mm³. For experimental metastasis studies, 0.5 × 10⁶ cells in single cell suspension in 100 µl PBS were injected into the lateral tail vein of five-week old male BALB/c nude mice. Mice were fed 2 mg/ml doxycycline in 4% sucrose to induce the shRNA expression in the appropriate groups, or 4% sucrose as a control. Bioluminesent imaging of metastatic growth was performed following cell injection using 125 mg/kg luciferin (Gold Biotechnology, St Louis, MO) and the PhotonImager Optima (BioSpace Lab, France).

Simmons J.L., Pierce C.J., Al-Ejeh F, & Boyle G.M. (2017). MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. Scientific Reports, 7, 10909.

+ Open protocol

+ Expand

Biodistribution of Milk Exosomes in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

To examine the biodistribution of milk-derived exosomes in whole animals, evidence of uptake and tissue distribution was obtained by labeling milk exosomes with a near-IR fluorescent label, DiR (Life Technologies, Carlsbad, Calif.), and treating female nude mice with a single dose of the exosomes administered by oral gavage, intravenously, intranasally, or intraperitoneally (2 mg Exo protein/mouse). Imaging (Biospace lab Photon Imager Optima) of the live animals showed a strong fluorescent signal, with the signal being detected even after 4 d. Harvesting of various organs following euthanasia and imaging showed that the oral gavage (FIG. 28), intravenous (FIG. 29), intranasal (FIG. 30), and intraperitoneal (FIG. 31) routes resulted in similar tissue distribution of the exosomes, with the exceptions that, with intravenous and intraperitoneal administration, the liver was the predominant site of distribution, and that, when intransal administration was used, the lung was the predominant site. These data indicate that various routes of administration could be utilized effectively for the delivery of the exosomes and for the selection of target organs.

US10420723B2. Milk-derived microvesicle compositions and related methods (2019-09-24). University of Louisville Research Foundation, Inc. [US]. Inventors: Ramesh C. Gupta [US], Radha Munagala [US], Farrukh Aqil [US], Jeyaprakash Jeyabalan [US].

+ Open protocol

+ Expand

In Vivo Bioluminescence Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

BLI was performed on days 2, 9, 20 and 23 using a Photon Imager Optima (Biospace Lab, France). For whole body in vivo images, animals were administered 150 μL D-luciferin (Biosynth, USA) intraperitoneally at 150 mg/kg. Four mice were imaged simultaneously per acquisition. Peak emission had previously been determined to be at approximately 15 minutes post-injection, so animals were anaesthetised at 12 minutes and placed within the imaging chamber. Images were acquired in a single, supine orientation, with a 10 s exposure time.

Ramasawmy R., Johnson S.P., Roberts T.A., Stuckey D.J., David A.L., Pedley R.B., Lythgoe M.F., Siow B, & Walker-Samuel S. (2016). Monitoring the Growth of an Orthotopic Tumour Xenograft Model: Multi-Modal Imaging Assessment with Benchtop MRI (1T), High-Field MRI (9.4T), Ultrasound and Bioluminescence. PLoS ONE, 11(5), e0156162.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!